PHÂN TÍCH CHI PHÍ – HỆ QUẢ CỦA CEFTAROLINE FOSAMIL TRONG ĐIỀU TRỊ VIÊM PHỔI MẮC PHẢI CỘNG ĐỒNG Ở NGƯỜI LỚN VÀ TRẺ EM TẠI VIỆT NAM

Abstract

Objectives: Analyze the cost and consequences associated with the use of Ceftaroline fosamil (Ceftaroline) as compared to Ceftriaxone for the treatment of community-acquired pneumonia in adult and pediatric inpatients in Vietnam. Materials and Methodology: The decision tree model was applied for the cost-consequence analysis, adopting the Health Insurance perspective. The analysis covered the period from inpatient admission to the hospital until discharge. Results: Compared to the group using Ceftriaxone as the initial treatment, in pediatric patients, using Ceftaroline significantly increased the treatment success rate (12.86%) and the total treatment cost per patient from 248 thousand VND. For adults, using Ceftaroline helps increase the treatment success rate (21.10% and 19,30%) and increases the total treatment cost per patient to 4.47 - 4.53 million VND relative to Levofloxacin and Ceftriaxone. Compared with Ceftriaxone, the additional cost for a successful treatment with the initial antibiotic Ceftaroline is 1.9 million VND (children) and 23.5 million VND (adults). The most common factors affecting the cost-effectiveness include the cost per vial of Ceftaroline, the duration of treatment with Ceftaroline, and the early response rate after 72 hours of therapy with Ceftaroline and Ceftriaxone. Probability sensitivity analysis results show that about 34.5% of pediatric patients treated with Ceftaroline will achieve higher effectiveness and reduce costs compared to Ceftriaxone. Conclusion: Based on the payer's perspective, Ceftaroline treatment enhances treatment success rates, reduces mortality rates, and incurs higher total average costs compared to Ceftriaxone and Levofloxacin. The inclusion of the new antibiotic (such as Ceftaroline) to the Medicines lists is essential given the increasing antibiotic resistance rate and the need to ensure the availability of antibiotics in the medicine lists.